STOCK TITAN

Mesoblast Ltd - MESO STOCK NEWS

Welcome to our dedicated news page for Mesoblast (Ticker: MESO), a resource for investors and traders seeking the latest updates and insights on Mesoblast.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mesoblast's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mesoblast's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
none
-
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.49%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
clinical trial covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.29%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.23%
Tags
clinical trial covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.79%
Tags
Mesoblast Ltd

Nasdaq:MESO

MESO Rankings

MESO Stock Data

570.76M
796.57M
0.75%
2.31%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Australia
Melbourne

About MESO

mesoblast; (asx: msb; nasdaq:meso) is a world leader in innovative cell-based medicines. we have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells (mlcs) to establish what we believe is the most advanced cellular medicines portfolio in the industry. our ‘off-the-shelf’ products are allogeneic - meaning cells from one donor may be used in many different recipients without the need for matching. our licensee in japan has launched its mlc-based product for acute graft versus host disease in children and adults in japan. it is the first allogeneic cell-based product in japan to be fully approved in japan. we believe we are well positioned to have the first industrially manufactured allogeneic cell-based product approved in the united states. our lead product candidates under investigation are: • mpc-150-im for chronic heart failure • mpc-06-id for chronic low back pain due to disc degeneration • msc-100-iv for acute graf